Calliditas: Further European progress and some take-away from the R&D update - Redeye

The Committee for Medicinal Products for Human Use (CHMP) of EMA recommends a full marketing authorisation for Kinpeygo in Europe and a target patient population of UPCR of ≥ 0.8g/g. EC can expect to make the formal decision by August 2024. Yesterday, Calliditas also provided an R&D update, including the lead product, Nefecon.

Länk till analysen i sin helhet: https://www.redeye.se/research/1013400/calliditas-further-european-progress-and-some-take-away-from-the-rd-update?utm_source=finwire&utm_medium=RSS